Get started
Author

Bengt Hamrén

Observed names: B Hamrén, B. Hamrén, BENGT HAMREN, Bengt Hamren, Hamren, B
ORCID: 0000-0001-5002-3399
Observed ORCID: 0000-0001-5002-3399
OpenAlex ID: A5060396305
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
2018 · Paul Morgan, Dean G. Brown, et al. · Nature Reviews Drug Discovery · 451
Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation
2015 · EFPIA MID3 Workgroup, SF Marshall, et al. · CPT Pharmacometrics & Systems Pharmacology · 373
PDF
Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment
2008 · B Hamrén, E Björk, et al. · Clinical Pharmacology & Therapeutics · 68
Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development
2012 · I Demin, B Hamrén, et al. · Clinical Pharmacology & Therapeutics · 55
A Model for Glucose, Insulin, and Beta‐Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes
2010 · Jakob Ribbing, Bengt Hamrén, et al. · The Journal of Clinical Pharmacology · 39
Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
2017 · Yasunori Aoki, Daniel Röshammar, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 37
PDF
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet
2017 · Gabriel Helmlinger, Nidal Al-Huniti, et al. · European Journal of Pharmaceutical Sciences · 33
Modelling and simulation to improve decision-making in clinical development
2005 · Carl-Fredrik Burman, Bengt Hamrén, et al. · Pharmaceutical Statistics · 31
Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
2004 · H Ericsson, B Hamrén, et al. · PubMed · 28
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
2019 · Victor Sokolov, Gabriel Helmlinger, et al. · Journal of Lipid Research · 23
Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
2018 · Magnus Åstrand, Carl Amilon, et al. · British Journal of Clinical Pharmacology · 22
PDF
Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes
2016 · Elin Nyman, Yvonne J. W. Rozendaal, et al. · Interface Focus · 21
Comparison of the exposure–response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus
2016 · J. Parkinson, W. Tang, et al. · Diabetes Obesity and Metabolism · 21
Pharmacokinetic‐Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus
2011 · Bengt Hamrén, K. Peter Öhman, et al. · The Journal of Clinical Pharmacology · 19
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
2021 · Yasunori Aoki, Bengt Hamrén, et al. · PLoS ONE · 17
PDF
Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease
2021 · Dinko Rekić, Virginie Kerbusch-Herben, et al. · Clinical Pharmacokinetics · 15
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion
2008 · Bengt Hamrén, Hans Ericsson, et al. · British Journal of Clinical Pharmacology · 15
PDF
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
2017 · Daniel Röshammar, Martin Bergstrand, et al. · International Journal of Clinical Pharmacology and Therapeutics · 14
PHARMACOKINETICS AND METABOLISM OF TESAGLITAZAR, A NOVEL DUAL-ACTING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α/γ AGONIST, AFTER A SINGLE ORAL AND INTRAVENOUS DOSE IN HUMANS
2004 · H. Ericsson, B. Hamrén, et al. · Drug Metabolism and Disposition · 14
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
2019 · Carl Amilon, Mohammad Niazi, et al. · Clinical Pharmacokinetics · 12
Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
2014 · John Maringwa, Matts Kågedal, et al. · The Journal of Clinical Pharmacology · 12
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
2022 · Johanna Melin, Weifeng Tang, et al. · The Journal of Clinical Pharmacology · 9
PDF
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II
2022 · Jane Knöchel, Catarina Nilsson, et al. · CPT Pharmacometrics & Systems Pharmacology · 8
PDF
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data
2022 · Yasunori Aoki, Claudia S. Cabrera, et al. · PLoS ONE · 8
PDF
Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
2019 · Joanna Parkinson, Weifeng Tang, et al. · Diabetes Obesity and Metabolism · 8
PDF
Works count: 47
Citation count: 1,425
H-index: 15
I10-index: 21
Year
Topic
Type